WO2013006050A9 - Peptides inducing or enhancing an immune response against prostate-specific membrane protein (psma) - Google Patents

Peptides inducing or enhancing an immune response against prostate-specific membrane protein (psma) Download PDF

Info

Publication number
WO2013006050A9
WO2013006050A9 PCT/NL2012/050469 NL2012050469W WO2013006050A9 WO 2013006050 A9 WO2013006050 A9 WO 2013006050A9 NL 2012050469 W NL2012050469 W NL 2012050469W WO 2013006050 A9 WO2013006050 A9 WO 2013006050A9
Authority
WO
WIPO (PCT)
Prior art keywords
psma
enhancing
immune response
membrane protein
response against
Prior art date
Application number
PCT/NL2012/050469
Other languages
French (fr)
Other versions
WO2013006050A1 (en
Inventor
Gerardus Johannes Platenburg
Wilhelmus Johannes Theodorus Alexander KREBBER
Cornelis Joseph Maria Melief
Original Assignee
Isa Pharmaceuticals B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isa Pharmaceuticals B.V. filed Critical Isa Pharmaceuticals B.V.
Publication of WO2013006050A1 publication Critical patent/WO2013006050A1/en
Publication of WO2013006050A9 publication Critical patent/WO2013006050A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Abstract

The present invention relates to the fields of medicine and immunology. In particular, it relates to novel peptides that may be used in the treatment, prevention and/or delay of a PSMA related disease or condition.
PCT/NL2012/050469 2011-07-06 2012-07-03 Peptides inducing or enhancing an immune response against prostate-specific membrane protein (PSMA) WO2013006050A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161504757P 2011-07-06 2011-07-06
EP11172914.1 2011-07-06
US61/504,757 2011-07-06
EP11172914 2011-07-06

Publications (2)

Publication Number Publication Date
WO2013006050A1 WO2013006050A1 (en) 2013-01-10
WO2013006050A9 true WO2013006050A9 (en) 2013-02-21

Family

ID=47437252

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2012/050469 WO2013006050A1 (en) 2011-07-06 2012-07-03 Peptides inducing or enhancing an immune response against prostate-specific membrane protein (PSMA)

Country Status (1)

Country Link
WO (1) WO2013006050A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2844282T3 (en) * 2012-05-04 2019-07-15 Pfizer PROSTATA ASSOCIATED ANTIGENES AND VACCINE-BASED IMMUNTERAPIREGIMENES
PE20171135A1 (en) * 2014-11-05 2017-08-09 Memorial Sloan Kettering Cancer Center METHODS TO SELECT A LINE OF T-CELLS AND DONOR THEM FOR ADOPTIVE CELLULAR THERAPY
CN109641039B (en) 2016-06-20 2023-08-04 Isa制药有限公司 Peptide vaccine formulations
GB201917699D0 (en) * 2019-12-04 2020-01-15 Ultimovacs Ab Vaccine conjugates

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU765822B2 (en) 1998-05-23 2003-10-02 Leiden University Medical Center CD40 binding molecules and CTL peptides for treating tumors
US20030118588A1 (en) 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
WO2001074845A2 (en) * 2000-03-31 2001-10-11 Aventis Pasteur Limited Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof
ES2724121T3 (en) 2000-12-08 2019-09-06 Academisch Ziekenhuis Leiden Long peptides of 22-45 amino acid residues that induce and / or improve specific immune responses for antigens
AU2007298494B2 (en) * 2006-09-21 2013-09-26 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
WO2011073215A2 (en) * 2009-12-14 2011-06-23 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof

Also Published As

Publication number Publication date
WO2013006050A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
EP3607074A4 (en) Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
EP3486256A3 (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
MX2019011952A (en) Anti-garp protein and uses thereof.
WO2014113490A3 (en) Immunogenic wt-1 peptides and methods of use thereof
EP3212795A4 (en) Rna guided eradication of human jc virus and other polyomaviruses
WO2017015622A3 (en) Gdf11 binding proteins and uses thereof
WO2016004389A3 (en) Monovalent binding proteins
WO2012024632A3 (en) Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus m2e
EP3256495A4 (en) Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
WO2011113019A3 (en) Ctla4 proteins and their uses
WO2011094259A3 (en) Cd127 binding proteins
WO2013183058A3 (en) Expanded device
EA201491481A1 (en) Allergen timofeed meadow and methods and applications for modulating immune response
MX2014004953A (en) Tyrosine based linkers for the releasable connection of peptides.
WO2012047267A3 (en) Polyvalent immunogen
WO2014160747A3 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
WO2015123493A3 (en) Compositions and methods for modulatuion of immune response
WO2016020882A3 (en) Angiopoetin-like 4 (angptl4) antibodies and methods of use
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
WO2013006050A9 (en) Peptides inducing or enhancing an immune response against prostate-specific membrane protein (psma)
EP3067423A4 (en) Human insecticidal gene and insecticidal peptide encoded thereby, and use thereof
WO2016016651A3 (en) Pfrh5 derived antigen for treatment of malaria
WO2016192819A3 (en) Modified peptides and their use for treating chronic inflammatory diseases
WO2015124928A3 (en) Surfactant protein d or helminths for treating infection or inflammation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12737912

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12737912

Country of ref document: EP

Kind code of ref document: A1